The Food and Drug Administration on Tuesday approved Roche's hepatitis C treatment that combines the company's drug Pegasys, an interferon-alpha compound approved separately by the FDA in October, and the antiviral drug ribavirin, marketed by Roche as Copegus. Combining inteferon and ribavirin has been the traditional hepatitis C treatment for several years, but previously available forms of interferon-alpha had to be injected three times per week. Pegasys, a long-lasting form of interferon, is injected only once a week. The FDA approved Roche's combination treatment after reviewing data that showed the once-a-week injections, when coupled with Copegus, were more effective in lowering hepatitis C viral levels than the standard combination therapy. Roche also is currently testing Pegasys for the possible treatment of hepatitis B.
Charlie Kirk DID say stoning gay people was the 'perfect law' — and these other heinous quotes